In a significant development for patients battling chronic graft-versus-host disease (GVHD), the U.S. Food and Drug Administration (FDA) has granted approval to Niktimvo™ (axatilimab-csfr), a groundbreaking anti-CSF-1R antibody. This approval marks a pivotal moment in...
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 27, 2024-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment...
We have some exciting news to share! We’re thrilled to announce that we are a founding member of the newly formed GVHD Alliance
This month’s telephone educational and support program will help cancer survivors and their families better understand the COVID vaccine and the important need for booster shots
GVHD EVENT DATE & TIME: Wednesday, July 21, 2021 - Noon to 1 pm EST This month's FREE telephone educational and support program will focus on the love/hate of steroid use as it relates to chronic GVHD. Dr. Masumi Ueda Oshima, Assistant Professor and Assistant...
GVHD EVENT DATE AND TIME: Friday, November 20th, 2020 1 pm to 3 pm EST Chronic GvHD Consensus Conference Patient Advocacy Summit Event Website and Registration: https://ncifrederick.cancer.gov/events/conferences/2020ChronicGVHDConsensus/advocacysummit Registration is...
EVENT DATE AND TIME: Tuesday, Oct. 20, 2020 Noon to 1:30 pm EST Be sure to note the various time zone start times as indicated here: 12 pm (Noon): Eastern Time 11 am: Central Time 10 am: Mountain Time 9 am: Pacific Time Survivorship Issues Following a Bone Marrow/Stem...
The 2020 Graft vs Host Disease National Symposium will be a virtual symposium at no charge.
KEYNOTE SPEAKER: Joseph H. Antin, MD Dana Farber Cancer Insitute Dr. Antin received his MD from Cornell University in 1978, and postgraduate training in hematology and medical oncology at DFCI and Brigham and Women's Hospital. He subsequently served as director of the...